Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions

被引：1
|
作者：
Goldberg, R. [1 ]
Beswick, L. [2 ]
Van Langenberg, D. [3 ]
Sally, B. [4 ,5 ]
Rosella, O. [2 ]
Gibson, P. [2 ]
Moore, G. [1 ]
机构：
[1] Monash Univ, Monash Hlth, Dept Gastroenterol, Melbourne, Vic 3004, Australia
[2] Alfred Hlth, Dept Gastroenterol, Melbourne, Vic, Australia
[3] Eastern Hlth, Dept Gastroenterol, Melbourne, Vic, Australia
[4] St Vincents Hosp, Melbourne, Vic, Australia
[5] Univ Melbourne, Gastroenterol, Melbourne, Vic, Australia
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60498-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P378
引用
收藏
页码：S223 / S223
页数：1
相关论文
共 50 条
  • [41] Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD
    Ulijn, Evy
    den Broeder, Nathan
    Wientjes, Maike
    van Herwaarden, Noortje
    Meek, Inger
    Tweehuysen, Lieke
    van der Maas, Aatke
    van den Bemt, Bart J. F.
    den Broeder, Alfons A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (07) : 867 - 873
  • [42] Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis
    Mori, Ayano
    Saito, Toshiharu
    Takahashi, Miho
    Shibata, Miho
    Tsuji, Goh
    Hatachi, Saori
    Takahashi, Soshi
    Kumagai, Shunichi
    [J]. PLOS ONE, 2020, 15 (12):
  • [43] Secondary Infliximab Treatment Failure in Crohn's Disease: Therapeutic Implications of Measuring Drug and Anti-Drug Antibodies by Three Different Binding Assays
    Steenholdt, Casper
    Brynskov, Jorn
    Thomsen, Ole
    Munck, Lars K.
    Fallingborg, Jan
    Christensen, Lisbet A.
    Pedersen, Gitte
    Kjeldsen, Jens
    Bendtzen, Klaus
    Ainsworth, Mark A.
    [J]. GASTROENTEROLOGY, 2013, 144 (05) : S773 - S773
  • [44] Relevance of anti-drug antibodies in context of supra-therapeutic anti-TNF concentrations
    Kim, J.
    Walshe, M.
    Borowski, K.
    Milgrom, R.
    Stempak, J.
    Lee, S. H.
    Croitoru, K.
    Silverberg, M. S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I933 - I934
  • [45] Phenytoin/valproic acid interactionBreakthrough seizures secondary to sub-therapeutic drug levels: case report
    [J]. Reactions Weekly, 2016, 1607 (1) : 342 - 342
  • [46] Discriminating Between Response Types in Infliximab-Treated Patients With Crohn's Disease: Sensitivity and Specificity of Combined Assessment of Infliximab Trough Levels and Anti-Drug Antibodies
    Steenholdt, Casper
    Thomsen, Ole O.
    Brynskov, Jorn
    Bendtzen, Klaus
    Ainsworth, Mark A.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S687 - S688
  • [47] Infliximab trough levels and anti-drug antibodies after induction predict long-term clinical remission in infliximab-treated patients with inflammatory bowel disease
    Bodini, G.
    Del Nero, L.
    Giannini, E. G.
    Tolone, S.
    De Bortoli, N.
    Anjali, J.
    Baldissarro, I.
    Savarino, V.
    Savarino, E.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S408 - S409
  • [48] Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels
    Ruiz-Argueello, Begona
    del Agua, Ainhoa Ruiz
    Torres, Nerea
    Monasterio, Alberto
    Martinez, Antonio
    Nagore, Daniel
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (12) : E287 - E289
  • [49] Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
    Jyssum, Ingrid
    Gehin, Johanna E.
    Sexton, Joseph
    Kristianslund, Eirik Klami
    Hu, Yi
    Warren, David John
    Kvien, Tore K.
    Haavardsholm, Espen A.
    Syversen, Silje Watterdal
    Bolstad, Nils
    Goll, Guro Lovik
    [J]. RHEUMATOLOGY, 2024, 63 (06) : 1746 - 1755
  • [50] ADALIMUMAB SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES: ASSOCIATION TO DISEASE ACTIVITY AND DRUG SURVIVAL IN INFLAMMATORY ARTHRITIS PATIENTS
    Jyssum, I.
    Gehin, J. E.
    Kristianslund, E.
    Sexton, J.
    Worren, D.
    Hu, Y.
    Kvien, T. K.
    Haavardsholm, E. A.
    Bolstad, N.
    Syversen, S. W.
    Goll, G. L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 421 - 422
12345